Akero Therapeutics said its NASH drug reduced liver fat in patients who were also taking a GLP-1 agonist.
The NASH-focused biotech on Monday released topline data from a Phase IIb trial for 32 patients with type 2 diabetes and F1-F3 liver fibrosis due to NASH who…
